Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
Simiao Yu,Jingxiao Wang,Haocheng Zheng,Ruilin Wang,Nadia Johnson,Tao Li,Ping Li,Jie Lin,Yuan Li,Jin Yan,Ying Zhang,Zhenyu Zhu,Xia Ding
DOI: https://doi.org/10.2147/JHC.S377768
2022-08-26
Journal of Hepatocellular Carcinoma
Abstract:Simiao Yu, 1, * Jingxiao Wang, 2, * Haocheng Zheng, 3, * Ruilin Wang, 4, * Nadia Johnson, 1 Tao Li, 3 Ping Li, 1 Jie Lin, 5 Yuan Li, 5 Jin Yan, 6 Ying Zhang, 6 Zhenyu Zhu, 6 Xia Ding 3, 7 1 Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, People's Republic of China; 2 School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China; 3 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China; 4 Department of Hepatology of Traditional Chinese Medicine, The Fifth Medical Center of PLA General Hospital, Beijing, 100039, People's Republic of China; 5 National Institute of Traditional Chinese Medicine Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China; 6 Department of Hepatobiliary Surgery, The Fifth Medical Center of PLA General Hospital, Beijing, 100039, People's Republic of China; 7 Centre of Research for Traditional Chinese Medicine Digestive, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China *These authors contributed equally to this work Correspondence: Xia Ding, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Email Zhenyu Zhu, Department of Hepatobiliary Surgery, The Fifth Medical Center of PLA General Hospital, Email Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and one of the deadliest cancers worldwide. As opposed to the majority of patients with HCC, approximately 20– 30% of cases of non-alcoholic steatohepatitis (NASH)-derived HCC develop malignant tumours in the absence of liver cirrhosis. NASH is characterized by metabolic dysregulation, chronic inflammation and cell death in the liver, which provide a favorable setting for the transformation of inflammation into cancer. This review aims to describe the pathogenesis and the underlying mechanism of the transition from inflammation to cancer in NASH. Keywords: non-alcoholic steatohepatitis, hepatocellular carcinoma, inflammation to cancer transition, metabolic dysregulation, immune microenvironment Primary liver cancer is the sixth most common cancer and the third leading cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC), an inflammation-associated cancer, accounts for approximately 80% of all primary liver cancers. 1 Chronic inflammation has long been acknowledged as one of the essential hallmarks of tumorigenesis and can lead directly to cancer progression. 2 As early as the 19th century, Rudolf Virchow suggested that cancer arises from inflammation sites by observing leukocytes within cancerous tissues. 3 Accumulating evidence highlights the key role of chronic inflammation in the initiation, progression, invasion, and metastasis of cancer. 4 HCC frequently develops following a multi-step process from chronic inflammation to fibrosis, cirrhosis and carcinoma. 5 The majority of HCC cases occur in the setting of cirrhosis. However, approximately 12% of patients progress into HCC absence of cirrhosis. 6 A systematic review and meta-analysis of nineteen studies with a total of168571participants reported that non-alcoholic steatohepatitis (NASH) was the most common cause of non-cirrhotic HCC. 7 A single center retrospective cross-sectional study showed that 34.6% of NASH-derived HCC patients did not have cirrhosis. 8 The prevalence of NASH has shown a rapid upward trend accompanying the improvement of living standards. Consequently, over the course of 20 years between the periods of 1995–1999 to 2010–2014, the prevalence of NASH-derived HCC also increased from 2.6% to 19.5%. 9 NASH has already become the second leading cause of liver transplantation related to HCC in the United States. 10,11 Therefore, clarifying the exact mechanism of the inflammation-to-cancer transition in NASH is in urgent need. This review provides an in-depth discussion of the pathogenesis underlying the evolution from inflammation to malignancy with the intent to advance the prevention, diagnosis, and treatment of NASH-derived HCC. The pathogenesis of NASH involves an intricate relationship between a multitude of pathological mechanisms. Among them, insulin resistance (IR), lipotoxicity caused by accumulation of lipids and lipid metabolites, and the infiltration of pro-inflammatory cells are the most vital factors triggering chronic inflammation that leads to hepatocyte injury and progression -Abstract Truncated-
oncology